Updated daily

Today in Migraine Science

The newest migraine studies, plus approvals, guideline changes, and other news. Explained in plain language, with every link going straight to the source.

No matches on this page. Try a different word.

Monday, November 16, 2026

New today
Randomized trial

Can an online therapy program help people with frequent migraine when it is added to their usual care? A team at the University of Gothenburg ran a randomized trial in 154 adults with frequent episodic or chronic migraine in Swedish primary care. Half kept their usual medical treatment, and half also worked through a therapist-guided, acceptance-based online cognitive behavioral therapy program, with written support from a psychologist. At 12 months, migraine-related disability had fallen more in the online therapy group, and mental health and well-being scores were higher after treatment and at 12 months. Monthly migraine days and pain intensity did not differ between the groups at any point. The authors say migraine days were self-reported, the trial may have been too small to detect modest effects, and most participants were women, which may limit how far the results apply to men.

Read the study Internet Interventions
Expert consensus

When should migraine prevention start, and how long should it continue? The headache study group of the Spanish Society of Neurology ran a two-round Delphi consensus with 88 migraine specialists in the first round and 48 in the second, built on a review of 171 publications. The panel agreed on all 14 statements. It recommends preventive treatment for people with 4 or more migraine or moderate-to-severe headache days a month and a real impact on quality of life. Good control is defined as fewer than 4 moderate-to-severe headache days a month over three months, and treatment should generally continue for at least 12 months after reaching it. People who respond only partly can switch to or combine CGRP antibodies, gepants and onabotulinumtoxinA (Botox). The recommendations come from expert agreement rather than new trial data, and they are written for the Spanish health system.

Read the study Neurological Sciences
Diagnostic study

Can a standard positional test tell vestibular migraine apart from benign paroxysmal positional vertigo (BPPV), the common inner-ear crystal problem? Both can cause dizziness when the head changes position. A team at Union Hospital in Wuhan, China compared 101 people with vestibular migraine and positional vertigo with 219 people with BPPV, using eye-movement recordings taken during the test. People with vestibular migraine were less likely to feel dizzy during the test (31 percent vs 100 percent) and less likely to have eye flickering, or nystagmus, that stopped within a minute (24 percent vs 92 percent). Their nystagmus was also slower and more often vertical. Five machine learning models built on these features separated the two conditions with an area under the curve of about 0.94. The authors say feeling dizzy during the test is part of how BPPV is diagnosed, which inflates its weight in the model, and that this single-center, retrospective study needs prospective testing at other centers.

Read the study Diagnostics
From the blog

Atogepant (Qulipta) vs Topiramate (Topamax): What the 545-Person TEMPLE Trial Found

In a 545-person head-to-head trial, fewer people stopped atogepant (Qulipta) because of side effects than topiramate (Topamax), and more had their migraine days cut in half.

Read the post MigraineScience

Previous days

Sunday, November 15, 2026

Can mild electrical stimulation of the trigeminal nerve through the ears ease migraine? Researchers at three universities in Turkey ran a randomized, sham-controlled trial in 102 people with migraine. Half received transcutaneous auricular trigeminal nerve stimulation on both ears for 20 minutes, three times a week for 12 weeks, and half had the same electrodes placed with no current. After 12 weeks, pain intensity and migraine-related disability were both lower with real stimulation than with sham. Sleep quality, the third main outcome, did not differ between the groups. The trial did not track monthly migraine days, which International Headache Society guidelines recommend for device trials, and the authors say blinding may not have held, since 73 percent of the active group correctly guessed their treatment.

Read the study →

How well does an implanted occipital nerve stimulator work for headache? With this device, wires placed under the skin at the back of the head deliver electrical pulses to the occipital nerves. A team at Nazarbayev University in Kazakhstan pulled together 9 systematic reviews, chosen from 207 records. Migraine was the condition studied most often, in 6 of the reviews, followed by occipital neuralgia in 4 and cluster headache in 3. The authors conclude that current evidence is insufficient to judge how well the stimulator works overall. Results looked more favorable for occipital neuralgia and cluster headache, while findings for migraine remain inconsistent. They note that the quality of the included reviews varied and that complications from the implanted hardware remain a notable concern.

Read the study →

How long do people stay on older migraine preventives before they reach a CGRP antibody? A team from Lundbeck, which makes eptinezumab (Vyepti), and the German research institute inav used health insurance claims for 137 adults in Germany who started their first CGRP antibody in late 2021, looking back over the previous five years. In that time they had tried an average of 2.6 conventional preventives, counting oral drugs and onabotulinumtoxinA (Botox). For most of these drugs, fewer than five people stayed on the same treatment for 180 days without a break. On average, the CGRP antibody started more than a year after the last older preventive was dispensed. The authors say the claims data could not show why people stopped, and the five-year look-back may have missed treatments tried earlier.

Read the study →
Blog

CGRP Antibody Injections in Everyday Care: What a 5,438-Patient Study Found In 5,438 people given CGRP antibody injections in Catalonia's public health system, about half of treatment courses cut headache days at least in half by 3 months, and acute medicine use fell 40 percent.

Read the post →
Saturday, November 14, 2026

How long do people with newly diagnosed migraine wait for preventive treatment, and does it depend on who treats them? A Texas Tech and Pfizer team reviewed Veterans Affairs records for 285,509 US veterans newly diagnosed with migraine between 2019 and 2024. Most (88.5 percent) were prescribed a migraine medicine, and 59.6 percent got at least one preventive. Among those on a preventive, the median wait from diagnosis to the first one was 46 days, and the median gap before moving to the next one was 128 days, which the authors say is longer than guidelines recommend. About 61 percent were managed only in primary care and 14 percent only by specialists. Veterans seen in specialty care were more than six times as likely to start a CGRP-targeted preventive and about 50 percent more likely to move on to a second preventive. The study was funded by Pfizer. The authors say the records held no data on migraine frequency or severity, so people managed in primary care may simply have had milder migraine, and onabotulinumtoxinA (Botox) given in clinic was not captured.

Read the study →

The Taiwan Headache Society has updated its 2022 advice on preventive treatment, this time focused on drugs that target CGRP. The new guideline lists CGRP-targeted therapy as a first-line option for both episodic and chronic migraine prevention. The antibodies covered are erenumab (Aimovig) and fremanezumab (Ajovy), along with galcanezumab (Emgality). Eptinezumab (Vyepti) is also included, as are two gepants, rimegepant (Nurtec ODT) and atogepant (Qulipta). People no longer need to fail several older preventives first, because the panel says starting early may control migraine better than waiting. It recommends preventive treatment for people with 4 or more headache days a month, significant disability, acute treatment that fails or cannot be used, or severe aura such as hemiplegic migraine, and says CGRP-targeted therapy may be continued for up to 12 months. The recommendations combine trial and meta-analysis evidence with expert panel opinion, and they are written for Taiwan's health system, where access and coverage rules differ from the US.

Read the study →

Adrenomedullin is a natural signaling molecule closely related to CGRP, and it is being studied as a possible new migraine drug target. A Danish Headache Center team tested whether it can trigger headache in people with persistent post-traumatic headache after a mild traumatic brain injury, none of whom had migraine before the injury. In a randomized, double-blind, placebo-controlled crossover trial, 21 adults received an adrenomedullin infusion on one day and a saline infusion on another. A migraine-like headache followed in 17 of 21 people (81 percent) after adrenomedullin and 4 of 21 (19 percent) after saline, starting a median of 30 minutes after the infusion. Fifteen said the headache resembled their usual headaches. The study was small and done at a single center, and the authors say the findings need confirmation in independent groups of patients before the pathway is pursued as a treatment target.

Read the study →

Where do family doctors in England send adults with headache? A Pfizer-funded team used primary care records from 1,569 practices between 2012 and 2023, covering 476,191 adults with migraine and 1,058,616 with other headache, each followed for a year. For migraine, the most common referrals were to general practitioners with an extended role in headache, at 8.6 per 100 person-years, followed by neurology at 6.4. For other headache, the most common referral was to ear, nose and throat specialists, at 11.8 per 100 person-years, ahead of neurology at 5.0. The authors suggest the high ear, nose and throat rate may reflect searching for other causes and missed vestibular or cranial autonomic symptoms, and they call for more training in migraine diagnosis for family doctors. They note that only prespecified services were counted, so referrals are probably underestimated, and that the reason for each referral was not recorded, so some may have been for other conditions.

Read the study →
Blog

Botox, Nerve Blocks, Stimulators, and Surgery for Chronic Migraine: What a 17-Review Umbrella Study Found A review of 17 systematic reviews on procedures for chronic migraine found onabotulinumtoxinA (Botox) has the strongest evidence. Nerve blocks may help short term, while stimulators and surgery rest on weak data.

Read the post →
Friday, November 13, 2026

Nerve deactivation surgery, sometimes called migraine surgery, releases or removes small nerves in the head and neck that are thought to set off attacks. It is offered to some people whose migraine has not responded to medicines, but not everyone benefits. A neurosurgery team in southern China studied 275 people with refractory migraine who had the surgery. 181 of them (65.8 percent) had at least a 50 percent drop in monthly migraine days, and 94 did not. Three things known before surgery were linked to the result: whether the person had aura, how many hours a day their headaches lasted, and how many types of painkiller they had used. The team combined these into a scoring chart, called a nomogram, that separated responders from non-responders with an area under the curve of 0.83, and 0.81 in a separate validation set, where 0.5 is chance and 1.0 is perfect. The abstract does not report how long patients were followed or whether the chart was tested at another hospital, and with no comparison group, the study cannot show how much of the improvement came from the surgery itself.

Read the study →
Blog

Does Your Acute Migraine Medicine Work Well Enough? What a 404-Patient Study Found In 404 people with migraine, those whose attack medicine worked poorly had about three times the disability of people with the same number of headache days whose medicine worked well.

Read the post →
Thursday, November 12, 2026

Anxiety and depression are common in people with migraine, and it has been unclear whether CGRP-targeted preventive drugs ease them, or whether any change simply follows fewer migraine days. A single-center study from the United Arab Emirates reviewed the records of 113 adults with migraine and documented anxiety or depression who started a CGRP antibody or a gepant, including eptinezumab (Vyepti) and atogepant (Qulipta). After 6 months, anxiety scores on the GAD-7 fell from 6.0 to 2.7 and depression scores on the PHQ-9 fell from 9.3 to 4.3, while monthly migraine days fell from 9.1 to 3.0. About 60 percent had a meaningful drop in anxiety and 55 percent in depression, with no clear difference between drugs. The size of the mood improvement was not linked to how much migraine days fell. The authors call the findings hypothesis-generating: there was no comparison group, the eptinezumab and atogepant subgroups were small, and they say controlled prospective studies are needed.

Read the study →

CGRP is the target of several migraine preventives, and it also plays a part in wound repair, which has raised the question of whether blocking it affects healing after surgery. A University of Pennsylvania team reviewed 81 women with migraine who had free flap breast reconstruction between 2018 and 2024. The 13 women (25 flaps) who took a CGRP inhibitor within 30 days before or after surgery were compared with 68 women (117 flaps) who did not. In the CGRP group, flap skin necrosis was more common (16.0 vs 5.1 percent), as was delayed wound healing (20.0 vs 8.5 percent), and wound problems took longer to heal (about 100 vs 76 days). The authors describe the link as a potential one and suggest reviewing these medicines before reconstruction. Only 13 women were on a CGRP inhibitor, the study was retrospective and from a single center, and the design cannot show the drugs caused the complications.

Read the study →

Vestibular migraine causes recurring episodes of vertigo, not always with headache, and standard preventives help some people much more than others. A systematic review from Saudi Arabia pulled together 21 studies with more than 12,000 participants, mostly middle-aged women, including trials, observational studies and case reports. Conventional preventives were linked to less frequent vertigo, less headache and less dizziness-related disability. The CGRP studies covered three antibodies, erenumab (Aimovig), fremanezumab (Ajovy) and galcanezumab (Emgality). They also covered two gepants, rimegepant (Nurtec ODT) and ubrogepant (Ubrelvy). These drugs were linked to fewer vertigo episodes and dizziness days, lower disability and better quality of life. Diagnosis still rests on clinical criteria, with vestibular testing and imaging used mainly to rule out other causes. The authors say randomized evidence is limited and head-to-head comparisons are scarce, so the review cannot say whether CGRP drugs work better than older preventives.

Read the study →
Blog

Probiotics for Migraine: What a 7-Trial Meta-Analysis Found A meta-analysis of 7 placebo-controlled trials linked probiotics to about 2 fewer migraine attacks a month, but the evidence was rated very low certainty and no single product was proven.

Read the post →
Wednesday, November 11, 2026

Greater occipital nerve blocks, injections of numbing medicine at the back of the head, are a common option when chronic migraine has not responded to preventive drugs. Pulsed radiofrequency sends short bursts of electrical current to the same nerve without destroying it. A study from Türkiye reviewed the records of 107 adults with chronic migraine that had not responded to at least two preventive treatments. All had four weekly ultrasound-guided nerve blocks with bupivacaine (Marcaine), and the 62 who agreed to it also had a 4-minute pulsed radiofrequency session at the fourth visit. Both groups improved from baseline. At 3 months, the combined group had lower pain scores (4.1 vs 5.2 out of 10), fewer attacks (4.2 vs 5.1), shorter attacks (13.6 vs 19.8 hours) and fewer days of pain medicine use (5.2 vs 6.6 a month). At 6 months, attacks were still shorter (14.1 vs 22.7 hours) and pain medicine use was lower (5.4 vs 8.0 days a month) in the combined group. No complications were reported. The authors note that patients chose their own treatment rather than being randomized, there was no sham control or blinding, pain scores already differed between the groups at the start, and follow-up lasted only 6 months.

Read the study →
Blog

Do You Have Migraine Without Knowing It? What a 601-Woman Study Found In a study of 601 women, half of those who met criteria for migraine had not identified it themselves, while women who said they had migraine were almost always right.

Read the post →
Tuesday, November 10, 2026

Wearable devices track signals such as heart rate, sleep and activity, and several research groups have built models that try to forecast migraine or headache attacks from them. A systematic review from Colombia searched three databases through May 2026 and found eight prediction-model studies in adults, covering warnings 20 to 40 minutes before onset, next-day forecasts and forecasts several days ahead. Accuracy, measured as area under the curve, ranged from 0.62 to 0.84, where 0.5 is chance and 1.0 is perfect. The largest study, of 146 adults over 21,550 days, reached 0.84 for next-day moderate-to-severe headache and 0.76 for a 3-day window. No study tested its model in a separate group of people, and only one checked whether predicted risks matched what happened. The authors rate five studies at high risk of bias, say the models may partly be telling apart people with frequent headaches from people with few rather than forecasting attacks within one person, and call the tools early proof-of-concept work, not validated alert systems.

Read the study →

Young people with migraine often report more anxiety, low mood and pain catastrophizing, which means expecting the worst about pain, but day-to-day links with disability have had little study. A Canadian team at a tertiary pediatric headache program followed 53 young people aged 8 to 18 (median age 15, 87 percent female, 57 percent with chronic migraine) for 30 days with electronic diaries, covering 769 headache days. On headache days, more catastrophizing and lower mood that same day went with more disability: each point higher on the catastrophizing scale went with about 3 percent more disability, and each point of better mood with about 8 percent less. A link with same-day anxiety did not hold after correcting for multiple comparisons. Mood and anxiety in the 24 to 48 hours before a headache day did not predict disability, and disability did not predict mood or anxiety afterward. The authors suggest psychological support aimed at the day of the attack itself. The sample was small and came from one specialty clinic, and the design shows associations, not cause.

Read the study →

Allostatic load is a score for the wear and tear that long-term stress puts on the body, built from markers of blood pressure, metabolism and inflammation. Researchers in China used US national survey data (NHANES) on 2,391 adults, of whom 475, or 22 percent, reported severe headache or migraine, and scored allostatic load from eight biomarkers in two different ways. After adjusting for other factors, each point higher on the score went with 10 to 14 percent higher odds of severe headache or migraine, and the result held with both scoring methods. The design is cross-sectional, so it cannot show which came first, and headache status was self-reported.

Read the study →
Blog

Heart Shunts, Migraine, and Stroke: What a 10-Year Study of 1,215 Patients Found In 1,215 people with migraine and a heart shunt found on a bubble test, a simple score using age, aura, and shunt type flagged who had higher stroke risk over 10 years. It was best at spotting who is at low risk.

Read the post →
Blog

Opioids as the First ER Treatment for Headache: What a 13,285-Person Study Found In 13,285 adults treated for headache in the ER, those given opioids first were more likely to come back within 72 hours than those given guideline-preferred drugs.

Read the post →
Monday, November 9, 2026

Headache care in low- and middle-income countries is limited by cost, training and distance, and there are few data from Nepal. As part of an International Headache Society initiative, 232 health care providers across Nepal answered a survey on their training, their patients and medication access, and more than half worked in Bagmati Province, which includes Kathmandu. 80.2 percent said they had training in migraine care, falling to 67.3 percent among non-physicians. 72 percent said patients had to pay for medication, and the median provider estimated that 40 percent of patients could not afford it. Triptans were reported as available for 18.5 percent of patients who could pay and 3.4 percent of those who could not, and no provider reported access to CGRP antibodies, gepants, ditans or onabotulinumtoxinA (Botox). Rural providers reported less access to triptans, topiramate (Topamax) and amitriptyline than urban providers. The authors say the figures are provider estimates, not patient records or pharmacy audits, and the sample leaned toward urban centers.

Read the study →
Blog

Migraine, Heart Attack, and Stroke Before and After Menopause: What a 2.2 Million-Woman Study Found In 2.2 million Korean women, migraine was tied to more heart attacks and ischemic strokes before and after menopause, with a larger relative increase before and more extra events after.

Read the post →
Sunday, November 8, 2026

Lower pain thresholds between attacks are often read as a sign of central sensitization, where the nervous system becomes more responsive to pain. A Norwegian study tested pressure, heat and cold pain thresholds on the head, neck and hand in 33 adults with migraine and 20 with tension-type headache, compared them with age- and sex-matched controls, and recorded one night of sleep with polysomnography. The migraine group was split by whether attacks usually started during sleep or on waking (15 people) or at other times (18 people). Only the group whose attacks did not start in sleep had lower pain thresholds than controls, at the neck and shoulder and for heat and cold on the palm, a pattern the authors read as central sensitization. In that group, more slow-wave bursts during sleep went with lower heat pain thresholds, and in episodic tension-type headache, more deep sleep went with higher thresholds. The authors say the analysis was exploratory with many comparisons, which raises the risk of chance findings, the subgroups were small, and sleep was recorded for one night only.

Read the study →
Blog

Raising the Eptinezumab (Vyepti) Dose to 300 mg: What a Study of Partial Responders Found A real-world study followed 57 people who only partly responded to eptinezumab (Vyepti) 100 mg. After moving up to 300 mg, about two in three reached a 50 percent drop in headache days.

Read the post →
Blog

Vitamins and Supplements for Migraine Prevention: What a 20-Trial Network Meta-Analysis Found A new network meta-analysis of 20 double-blind trials ranks vitamins and supplements for migraine prevention. Riboflavin 400 mg had the most reliable evidence, and magnesium showed no benefit.

Read the post →
Saturday, November 7, 2026

OnabotulinumtoxinA (Botox) and topiramate (Topamax) are both used to prevent chronic migraine, and onabotulinumtoxinA costs more per treatment. A cost-effectiveness analysis used results from the FORWARD randomized trial to build a 2-year economic model of US adults with chronic migraine, from the point of view of the insurer. The model estimated that people on onabotulinumtoxinA had about 123 fewer headache days than people on topiramate over 2 years, at an extra cost of $4,639 per person. That works out to about $38 per headache day avoided and $63,646 per quality-adjusted life year gained, and the results held across the sensitivity analyses the authors ran. Part of the higher drug cost was offset by lower spending on other health care and acute treatment. This is a model built on trial data, not a measure of actual spending, and its results depend on assumptions such as how often people stop topiramate. One author works for AbbVie, which makes Botox, and the article is copyrighted to AbbVie.

Read the study →

Childhood trauma has been linked to a higher risk of migraine in adulthood, but how common it is among Australian adults with migraine was not known. A survey at a tertiary headache clinic in Melbourne asked 514 adults with neurologist-confirmed migraine to complete the adverse childhood experiences questionnaire. 81.5 percent reported at least one traumatic childhood event, and 38.5 percent had a score of 4 or more, which the authors define as clinically significant. Verbal abuse was the most common exposure (48.1 percent), followed by a parent with a psychiatric diagnosis (43.4 percent) and emotional neglect (42.6 percent). Neglect-type trauma was linked to higher odds of chronic migraine, but the links with physical abuse and emotional neglect on their own lost significance after correction for multiple testing. The authors say only 40 percent of those invited responded, answers relied on recall, the timing of trauma relative to migraine onset was not known, and larger studies with a control group are needed.

Read the study →

Migraine is common in people with multiple sclerosis (MS), and few studies have looked at it outside Western countries. A cross-sectional study at a tertiary center in Egypt assessed 296 adults with MS for migraine using the ICHD-3 criteria. 27.4 percent had migraine. Women had higher odds of migraine than men, and so did people currently taking interferon compared with other MS treatments. People with MS and migraine reported fatigue more often (78 percent vs 64 percent) and had lower mental quality-of-life scores (median 39 vs 50), while physical quality-of-life scores did not differ. The study was cross-sectional and from a single center, so it shows associations at one point in time, not cause.

Read the study →

Migraine with aura and a transient ischemic attack (a brief, stroke-like episode) can look alike in the emergency department, and a normal diffusion MRI does not tell them apart. A retrospective study at a university hospital in Ankara, Turkey, reviewed susceptibility-weighted MRI scans of 290 people with stroke-like symptoms and normal diffusion imaging: 21 had migraine with aura and 269 had a transient ischemic attack. Asymmetry of the brain's veins on the side matching the symptoms appeared in 90.5 percent of the migraine with aura group and 16.4 percent of the transient ischemic attack group, where it was mostly mild. The researchers built a score from these vein signs plus age and symptoms; at its chosen cutoff it flagged 71.4 percent of migraine with aura cases and correctly ruled out 95.9 percent of transient ischemic attacks. The authors say only 21 people had migraine with aura, the score was built and tested in the same group, and it needs independent validation before it is used to guide diagnosis.

Read the study →
Friday, November 6, 2026

Many people with migraine take vitamins or supplements for prevention, but these have rarely been compared with each other. A network meta-analysis pooled 20 double-blind randomized trials with 1,829 participants testing riboflavin, coenzyme Q10, magnesium, vitamin D3 and B vitamins. In adults, riboflavin 400 mg gave the most consistent result, with about 2 fewer migraine attacks a month than placebo, at moderate certainty. Vitamin D3, vitamin B12 and vitamin B6 showed similar or larger drops, but each estimate came from one or two small trials and was graded low or very low certainty. Coenzyme Q10 400 mg shortened attacks by about 3.3 hours and lowered pain severity. Magnesium showed no detected benefit on any outcome. The authors say several comparisons rested on few studies and the responder results were imprecise, so the findings should be interpreted cautiously.

Read the study →

Lasmiditan (Reyvow) and rimegepant (Nurtec ODT) both treat migraine attacks, but they have not been compared directly in everyday care. Italian researchers pooled two prospective real-world studies in which 249 adults, 58 taking lasmiditan and 191 taking rimegepant, logged their first treated attack in an electronic diary. Pain freedom at 2 hours was 43.5 percent with rimegepant and 32.8 percent with lasmiditan, a difference that was not statistically significant. Side effects were reported by 53.4 percent of people after lasmiditan and 11.5 percent after rimegepant. The authors say the comparison was indirect, not a head-to-head trial, that the two groups differed slightly at baseline, and that needing a neurologist's prescription may have selected people whose migraine is harder to treat.

Read the study →

Radiofrequency ablation of the posterior nasal nerves is a procedure used for chronic rhinitis, and some people treated with it have reported fewer migraine attacks. A single-arm feasibility study at six US centers gave 24 adults with chronic migraine one ablation session on both sides of the nose and followed them for 6 months; 21 completed follow-up. Monthly migraine headache days fell by 5 to 7.5 days across the follow-up months, and 58 to 77 percent of participants had at least a 50 percent reduction. One person had a nosebleed 11 days after the procedure and was admitted to the hospital for observation and discharged the same day. The authors say there was no control group and no blinding, so a placebo effect cannot be separated from the procedure, and the sample was small. The study was designed and funded by Neurent Medical, which makes the device, and three of the four authors consult for the company.

Read the study →

Black and Indigenous communities have worse headache outcomes than other groups, and their experience of care is rarely studied. Researchers at Women's College Hospital in Toronto interviewed Black adults with headache in the Greater Toronto Area and analyzed 10 of the 12 interviews. Participants described delays in diagnosis, negative experiences in emergency departments, little education about headache, and difficulty getting effective medication. Barriers to specialist care included time off work, transportation costs, lack of referrals and long wait times. Their suggestions included specialist clinics located in Black communities, continued virtual care, and clinic staff who reflect the communities they serve. The authors note that this was not a comparative study, and that people with headache face barriers to care regardless of race, ethnicity or socioeconomic status.

Read the study →
Thursday, November 5, 2026

CGRP antibodies were tested in clinical trials, but less is known about how they perform in everyday care. A retrospective cohort study used registry and billing data from the Catalan Health Service in Spain to follow 5,438 adults treated with erenumab (Aimovig), fremanezumab (Ajovy) or galcanezumab (Emgality) between 2019 and 2023, across 7,270 courses of treatment. At 3 months, 48 percent of evaluable courses cut monthly migraine days by at least half, and 57.4 percent cut them by at least 30 percent. Average monthly migraine days fell from 16.7 at baseline to 9.1 at 9 months, and use of acute medication fell by 40 percent. Average yearly drug cost per patient rose 33 percent from 2019 to 2023. The authors say the retrospective design may leave residual confounding, that fewer treatment courses could be evaluated at 9 months, and that safety was not analyzed.

Read the study →

Many women with migraine are of childbearing age, and little is known about how the disease shapes decisions about pregnancy. A cross-sectional study at six public hospitals in Spain surveyed 162 women aged 18 to 49 with episodic or chronic migraine. Migraine had influenced reproductive decisions for 30 percent of them, most often by leading them to postpone pregnancy (24 percent), while 6 percent had decided against having children. The most common concerns were being unable to care for children during migraine attacks (80 percent), passing migraine on to a child (73 percent) and the risk that treatment could harm the baby (60 percent). The authors say some of these beliefs may not match current evidence and could be addressed in preconception counseling. Women were recruited at specialized headache units, which the authors say may not reflect women seen in primary care, and the study had no comparison group of women without migraine.

Read the study →

Researchers have proposed that gut bacteria may play a role in migraine. A systematic review and meta-analysis pooled 7 placebo-controlled trials of probiotics with 612 participants, 5 in adults and 2 in children. Probiotics were linked to about 2 fewer migraine attacks a month than placebo. The drops in pain severity (about 1 point on a 10-point scale) and in disability were not statistically significant. The authors graded the certainty of the evidence as very low and say differences between the trials limit how far the results apply.

Read the study →
Blog

Does Migraine Go Away After Menopause? What a 315-Woman Study Found In a clinic study of 315 women with migraine before menopause, 219 still had attacks afterward, though fewer and milder. A family history of migraine and insomnia were linked to migraine continuing.

Read the post →
Blog

Memory and Concentration Problems With Migraine: Do They Improve When Prevention Works? In 96 adults starting a CGRP antibody or onabotulinumtoxinA (Botox), people whose migraine responded reported a bigger improvement in memory and concentration complaints than people whose migraine did not.

Read the post →
Wednesday, November 4, 2026

Migraine often eases after menopause, but many women keep having attacks. A retrospective study across five headache clinics in Egypt interviewed 315 women born between 1971 and 1978 who had migraine before menopause: 219 still had migraine afterward and 96 no longer did. Even when migraine persisted, it was milder after menopause, with median monthly migraine days falling from 8 to 6, median pain scores falling from 7 to 6 out of 10, and fewer women reporting aura (61 vs 53 percent). Persistence was linked to having a first-degree relative with migraine (adjusted odds ratio 1.92) and to insomnia (2.22). Surgical menopause showed a stronger link (4.00), but the authors say that estimate was imprecise because few women had it. They also say the clinic-based sample limits how far the results apply to women with migraine in general.

Read the study →

Migraine is usually measured by its attacks, but many people also have symptoms on the days in between. An international group of headache specialists reviewed research from the past 10 years on this interictal phase. They report that between 26 and 76 percent of people with migraine have symptoms between attacks, including sensitivity to light, sound, smell or touch, brain fog, dizziness and mood changes, and that these add to lost work time and lower quality of life. Non-specific preventives often do not ease these symptoms, while CGRP-targeted drugs and onabotulinumtoxinA (Botox) have shown promising results on measures such as the Migraine Interictal Burden Scale. This is a narrative review, not a systematic one, and the authors say interictal symptoms still lack standard definitions and outcome measures for clinical practice.

Read the study →

Peripheral nerve blocks, injections near nerves in the scalp and face, are used for headache in adults but have been little studied in children. A prospective study at the headache clinic of Children's National Hospital in Washington, DC, surveyed 16 patients aged 10 to 19 before and after nerve blocks at 32 visits between 2020 and 2022; most had migraine without aura. Average pain fell from 4.4 to 2.8 on a 10-point scale after the injections. When the group was split by diagnosis, only patients with migraine without aura had a significant drop. The study had no comparison group, and the authors describe the findings as preliminary.

Read the study →
Blog

Does Rimegepant (Nurtec ODT) Work Every Time? What a 377-Attack Study Found In 191 people who logged 377 migraine attacks, rimegepant (Nurtec ODT) gave pain freedom at 2 hours in 45% of attacks. For most people, the response changed from one attack to the next.

Read the post →
Tuesday, November 3, 2026

Doctors usually judge how severe migraine is by counting headache days, but how well acute treatment works for each attack may matter too. A cross-sectional study at one headache center in Chongqing, China, enrolled 404 consecutive patients with migraine and scored their response to acute treatment with a 12-item questionnaire. Among people with fewer than 8 headache days a month, those with a poor response to acute treatment had about three times the disability score of those with a good response (median 12 vs 4), although both groups had a median of 3 headache days a month. After adjustment for other factors, low-frequency patients with a poor response were about as disabled as high-frequency patients with a good response, despite a fivefold gap in headache days (3 vs 15). In the adjusted model, treatment response added about as much to disability as headache frequency did, and less than depression scores. The authors say the cross-sectional design cannot show cause, a single tertiary center may not reflect community care, and every measure was self-reported at the same visit.

Read the study →

People with migraine have small white matter lesions on brain MRI more often than other people, and one theory is that some come from tiny areas of reduced blood flow. A proof-of-concept study in Rome measured platelet aggregation, an early step in clot formation, in 34 people with migraine (20 with white matter lesions and 14 without) and 34 matched healthy volunteers. Overall, platelets from people with migraine aggregated less in response to epinephrine than those of the healthy volunteers. People in the top quarter of lesion volume showed higher epinephrine-induced aggregation than those with smaller lesions or none, at levels similar to the healthy volunteers. The authors read this as a possible sign that reduced blood flow contributes to the lesions in some patients, which this design cannot confirm. They name the small sample and the mix of people with and without aura as the main limitations.

Read the study →
Monday, November 2, 2026

A team in Beijing used Global Burden of Disease 2023 estimates to measure what migraine costs in health and work among women aged 20 to 64 in Western Europe, projected from 2023 to 2029. Over those seven years, the model put the total at about 10.9 million disability-adjusted life years, a measure of healthy life lost, and 1.08 million productivity-adjusted life years, a measure of working life lost to ill health. Valued in money, the lost productivity came to about Int$69.9 billion in 2021 international dollars, with a sensitivity range of Int$66.1 billion to Int$76.3 billion. Among the countries with data, Belgium had the highest 2023 rate, at 1,443.6 disability-adjusted life years per 100,000 women. The figures are modeled projections, and the authors say the dollar estimate should not be read as observed economic loss or as savings that treatment would deliver.

Read the study →

Migraine may affect how well people control their eye movements, but it is unclear whether this differs between episodic and chronic migraine. A cross-sectional study from Guangzhou, China, tested 242 people with migraine and 47 healthy controls on a set of computer-tracked eye movement tasks; 199 had episodic migraine and 41 had chronic migraine. Compared with controls, people with migraine had a slower peak speed on the antisaccade task, which asks you to look away from a target, and the authors read this as weaker inhibitory control. Compared with episodic migraine, chronic migraine was linked to slower and less accurate eye movements, including longer reaction times, lower speed, poorer accuracy when looking toward a remembered location and more failures to suppress a reflexive glance, with small to moderate effect sizes. The analyses were exploratory, with no correction for multiple comparisons, and the authors say the findings need confirmation in larger, independent cohorts.

Read the study →
Sunday, November 1, 2026

Migraine is a leading cause of disability in women of childbearing age. A Chinese analysis of Global Burden of Disease 2023 estimates tracked migraine in this group in China from 1990 to 2023 and projected it to 2045. Estimated cases rose from about 60.9 million to 64.6 million, while new cases each year fell slightly, from 4.8 million to 4.7 million. Age-standardized rates of prevalence, new cases and disability all edged up, by about 0.2 to 0.3 percent a year, and the largest number of cases was among women aged 35 to 39. The model projects fewer total cases by 2045 but higher age-standardized rates, which the authors say suggests population changes may be hiding a rising underlying trend. The figures are modeled estimates rather than direct counts, and the authors say the wide uncertainty intervals mean the modest changes in absolute burden should be read with caution.

Read the study →
Blog

Acrylamide in Migraine Ice Caps: What Two New Studies Found Two 2026 studies found acrylamide, a nerve toxin, at thousands of ppm in the gel of some migraine ice caps. The post covers what that means for people who wear them and what the brands disclose.

Read the post →
Saturday, October 31, 2026

Headache is a common side effect after COVID-19 vaccination, and many people with migraine worry the shot could push episodic migraine toward chronic migraine. A prospective study at one clinic in Jeddah, Saudi Arabia, followed 60 adults with episodic migraine for six months: 30 vaccinated against COVID-19 and 30 unvaccinated. At six months, chronic migraine had developed in 3 of the 30 vaccinated and 6 of the 30 unvaccinated patients (OR 0.44, 95% CI 0.10 to 1.97), and every change to chronic migraine happened within the first three months. The difference was not statistically significant in either direction. The authors say the group was small, no sample-size calculation was done, and the wide confidence intervals rule out firm conclusions about harm or benefit.

Read the study →

An Italian study looked back at 296 people with fibromyalgia who had a skin biopsy to measure small nerve fibers. Of these, 138 (46.6 percent) also had migraine, 41 of them chronic migraine, and 191 (64.5 percent) had reduced nerve fiber density, which was equally common with or without migraine. The main analysis found no overall difference in pain, disability, associated symptoms or psychological scores by migraine type or small fiber damage. In exploratory analyses, people with both chronic migraine and small fiber damage reported more disability and more associated symptoms. The design was retrospective and cross-sectional, and the authors say the exploratory findings need confirmation in prospective studies.

Read the study →

CGRP is the molecule targeted by drugs such as erenumab (Aimovig) and atogepant (Qulipta), and blood CGRP has been proposed as a marker of treatment response. An Italian pilot study gave 52 adults with episodic migraine 10 sessions of manual acupuncture and measured CGRP in their blood before and one week after the last session. Blood CGRP levels did not change (60.9 vs 62.4 pg/ml). Migraine days fell by a median of 1.5 a month, pain scores dropped 1 point on a 10-point scale, and acute medication use and HIT-6 disability scores also improved. Every patient received acupuncture, and the authors say this single-arm design cannot show that acupuncture caused the improvement, so controlled studies are needed.

Read the study →
Blog

Exercise and Migraine: What a 1,828-Person Study Found In a survey of 1,828 people with migraine, about a quarter said exercise triggers headache and a quarter said it eases headache. Frequent attacks, allodynia, and anxiety shaped who reported which.

Read the post →
Thursday, October 29, 2026

Guidelines favor dopamine-receptor antagonists over opioids as the first emergency treatment for migraine. A two-center US study looked back at 13,285 adults treated for headache in the emergency department. Among those sent home, people whose first drug was an opioid were more likely to return for any reason within 72 hours (6.8 percent vs 3.8 percent after adjustment, RR 1.78, 95% CI 1.31 to 2.32) and within seven days (10.7 vs 6.6 percent). The opioid group was older and more often triaged as high acuity. When only headache-related returns were counted, the difference was no longer statistically significant. The authors say the design cannot show that changing the first drug would change return rates, and that the weaker headache-only result does not justify prescribing opioids.

Read the study →

A Portuguese study at two headache centers asked 96 adults about memory and concentration problems before and 3 to 6 months after starting prevention: 65 started a CGRP antibody and 31 started onabotulinumtoxinA (Botox). The 51 who responded to treatment reported more improvement in these symptoms than nonresponders, and the type of preventive made no difference. In people with depression symptoms at the start, the cognitive gains tracked improvement in mood. In those without, they tracked treatment response only. Ninety-eight percent were women, symptoms were self-reported rather than tested, and with no untreated comparison group the design cannot show that treatment caused the change.

Read the study →

An online survey of 1,763 adults in Egypt, Sudan, Algeria and Libya found that 352 (20 percent) reported a doctor's diagnosis of migraine. Only 19.6 percent of them had gone three months without an attack, and 26.7 percent had severe disability on the MIDAS scale. Among those still having attacks, 39.9 percent used no medication for relief. A family history of migraine was linked to about five times the odds of reporting a diagnosis (adjusted OR 5.13), and men had lower odds (0.56). The authors say convenience sampling skewed the group toward younger, urban, digitally literate women and likely toward people with severe headaches, so the 20 percent figure cannot be read as regional prevalence, and diagnoses and medication use were self-reported.

Read the study →
Blog

CGRP Migraine Drugs and Blood Pressure: What a 6,361-Patient Study Found A 6,361-patient study found CGRP migraine preventives did not raise blood pressure faster than in similar patients not taking them. Atogepant (Qulipta) users also lost the most weight.

Read the post →
Blog

How Migraine Is Treated After Diagnosis in the US: What a 154,353-Person Study Found Nearly half of US adults newly diagnosed with migraine filled an opioid prescription within 3 years, while fewer than 1 in 10 started prevention with a CGRP antibody.

Read the post →
Wednesday, October 28, 2026

A Chinese umbrella review brought together 17 systematic reviews of procedures for chronic migraine, including onabotulinumtoxinA (Botox), greater occipital nerve blocks, acupuncture, implanted occipital nerve stimulators and surgery. Botox had the most established evidence. Occipital nerve blocks may reduce headache days and severity in the short term, but that evidence was low certainty and lasting benefit is uncertain. Evidence for adding a CGRP antibody to Botox came mostly from uncontrolled studies, and evidence for acupuncture, other nerve blocks and surgery was limited. Most of the evidence was rated low or very low certainty, and the authors name wide differences in protocols, comparators and follow-up as the main limitation.

Read the study →

A single-center Spanish study looked back over 18 years at 207 people who received onabotulinumtoxinA (Botox) after trying several oral preventives: 136 with chronic migraine and 71 with high-frequency episodic migraine, a group Botox is not approved for in the US. Monthly headache days fell by at least half in 65.4 percent of the chronic group and 71.8 percent of the episodic group. Among responders, the benefit from each round lasted a mean of about 3.7 months. By the end of follow-up, 42.6 percent and 57.8 percent were still on Botox. There was no control group, and the authors say the episodic results are exploratory and cannot establish efficacy.

Read the study →

Doctors use two blood markers, sFlt-1 and PlGF, and the ratio between them to help predict preeclampsia. A Dutch study looked back at 234 pregnant women with suspected or confirmed high blood pressure disorders of pregnancy, 91 of whom had migraine. Within each diagnosis group, including preeclampsia and gestational hypertension, migraine was not linked to different marker levels after adjusting for age, gestational age and smoking. The authors conclude the test may not need to be read differently in women with migraine. Migraine history was assessed retrospectively, and the authors say a separate finding in the pooled group needs a prospective study.

Read the study →

A Turkish study had parents of 197 children and teens aged 6 to 18 complete a pediatric sleep questionnaire: 76 had migraine, 27 had episodic tension-type headache and 94 were healthy schoolchildren. Scores pointing to sleep problems appeared in 58.3 percent of children with headache and 27.7 percent of healthy children. The difference came mainly from night waking and behavior items, not snoring, and migraine and tension-type headache scored about the same. The authors recommend sleep screening for both. The design cannot show cause, sleep was reported by parents only, and patients came from a clinic while controls came from a school.

Read the study →
Tuesday, October 27, 2026

An Italian multicenter study followed 191 people who used rimegepant (Nurtec ODT) 75 mg for up to four migraine attacks, logging pain every 30 minutes in an electronic diary. Across 377 treated attacks, 44.6 percent were pain-free at two hours. Of the 110 people who treated at least two attacks, 36.4 percent were pain-free at two hours in two or more of them. Pain freedom was more likely in women, in people with fewer monthly migraine days, and in people not also taking a CGRP antibody for prevention. Side effects were reported by 11.5 percent, with no new safety signals. There was no placebo comparison, and only 30 people reached a fourth treated attack.

Read the study →

A study with several Pfizer authors used US insurance claims to follow 154,353 adults for three years after a first migraine diagnosis. Primary care made 47 percent of the diagnoses and neurology 18 percent. Within three years, 72.1 percent filled a migraine prescription. The first acute drug was most often an NSAID (62.8 percent), with triptans at 35 percent. The first preventive was most often a beta blocker (23.2 percent) or an anticonvulsant (21.6 percent), while CGRP antibodies came first for 8.1 percent and gepants for 1.2 percent. Opioid prescriptions were filled by 46.1 percent and butalbital by 12.5 percent. Claims do not show whether a drug was prescribed for migraine or actually taken, and the authors describe every analysis as descriptive.

Read the study →

European doctors use a tool called SCORE2 to estimate a person's 10-year risk of heart attack and stroke. A Swedish screening program measured it in 9,190 people aged 40 and 50, of whom 875 had a migraine diagnosis in a regional register. Migraine did not change the odds of a moderate or high score: the odds ratio was 0.60 (95% CI 0.22 to 1.32) in women and 1.13 (0.80 to 1.58) in men, and adjusting for age, education and country of birth barely moved either. Migraine with and without aura could not be told apart in 72 percent of cases. The authors say the study could not rule out an association.

Read the study →

A Polish systematic review gathered 13 clinical trials from 2015 to 2025, 12 of them randomized, covering 1,021 adults with migraine who received physiotherapy, mainly manual therapy and exercise therapy. Eight of the 13 trials improved at least one main outcome, such as pain intensity or disability scores, and four reported a drop in migraine frequency. Results were inconsistent, and several trials found no significant difference against the control group. The authors did not pool the data, and they name wide differences in treatment protocols, outcome measures and follow-up length as the main limitation.

Read the study →
Monday, October 26, 2026

A 12-month record review of 6,361 patients at the Jefferson Headache Center. Blood pressure rose in the control group too, by 0.16 mmHg a month. Erenumab (Aimovig) rose 0.11 mmHg a month, not significantly different from controls, while atogepant (Qulipta), fremanezumab (Ajovy) and galcanezumab (Emgality) fell faster than controls. One center, using chart readings rather than protocol measurement.

Read the study →

A retrospective series of 30 people with high-frequency episodic or chronic migraine treated with lidocaine to the sphenopalatine ganglion through a nasal catheter. Monthly migraine days fell from 19.5 to 11.5 at one month but were back to 16.5 by three months. Side effects were minor. No control group, and the authors call the findings preliminary.

Read the study →
Sunday, October 25, 2026

A clinical review of menopause across five neurological conditions. Migraine often worsens through perimenopause in people whose attacks track estrogen, then settles afterward. On hormone therapy the authors favor transdermal over oral, at or below a 50 microgram estradiol patch or 1.5 mg a day of 0.06 percent gel, and describe a better risk window before age 60 or within ten years of menopause.

Read the review →

A randomized placebo-controlled trial of greater occipital nerve block in 48 people with menstrual migraine. Pain scores went from 8.75 to 3.80 on bupivacaine against 8.71 to 7.16 on saline, with gains holding at six months. The authors note that a local anesthetic makes the scalp numb, so blinding was imperfect.

Read the study →

Matched US insurance claims for adults with chronic migraine. Those starting a preventive CGRP drug cut triptan use substantially, with an odds ratio of 0.57. Opioid use fell slightly but that result did not survive restricting to neurologist prescribers, which suggests it reflects who was prescribing rather than the drug.

Read the study →

A four-item score for stroke risk in migraine patients with a heart shunt, built on 978 patients and validated on 237 over ten years. Points for age 50 or over, aura, a permanent shunt and a large one. Top scores carried a 21.8 percent ten-year risk of unexplained stroke against 4.7 percent at the bottom, but the score rules people out far better than it rules them in.

Read the study →
Blog

Pets and Migraine: What a 3,017-Person, 2-Year Study Found People who kept a pet had fewer attacks and better sleep, those who acquired one improved, and those who gave one up lost most of the gain. Why a result that neat still cannot show pets caused it.

Read the post →
Blog

Migraine Research Statistics Explained: A Plain-Language Glossary Odds ratios, hazard ratios, confidence intervals, number needed to treat, and why a study can be statistically significant and still not matter.

Read the post →
Friday, October 23, 2026

57 adults who got a partial response to eptinezumab (Vyepti) 100 mg moved to 300 mg rather than switching drugs. 65 percent had halved their headache days after two cycles at the higher dose, with monthly headache days going from 18.7 to 13.3 to 8.8. Prior erenumab (Aimovig) exposure predicted a worse response. Uncontrolled and self-selected.

Read the study →

89 people in Japan took rimegepant (Nurtec ODT) after triptans, lasmiditan (Reyvow) or both had failed or could not be used. Three quarters had already tried a CGRP antibody. Pain scores fell from 77 to 18 at two hours and 0 at four, and 82 percent asked to keep the prescription.

Read the study →

160 children with vestibular migraine at Boston Children's. Topiramate (Topamax) led the preventives at 68 percent major improvement in dizziness against 38 percent for cyproheptadine (Periactin), and triptans beat meclizine (Antivert) for rescue. Retrospective, graded from the chart.

Read the study →

90 people wore activity trackers for 14 days and did a home sleep apnea test. The vestibular migraine group slept least with a two-hour weekday to weekend shift, positional vertigo showed an apnea-hypopnea index of 31.5, and persistent postural-perceptual dizziness had the best measured sleep and the worst opinion of it.

Read the study →
Blog

Plastic Surgeons Are Pushing Hard for Migraine Surgery Right Now. Read This Before Anyone Operates on You. Four promotional pieces in one journal in seven weeks, no sham-controlled trial among them, and all 20 systematic reviews on the procedure rated critically low in quality.

Read the post →
Wednesday, October 21, 2026

100 people with migraine and 102 controls had the back of the eye scanned. Both the nerve fiber layer and the ganglion cell layer were thinner in the migraine group, more so in chronic migraine. Cross-sectional, so the direction is unknown, and it does not mean anyone loses vision.

Read the study →

A review of the cerebellum in migraine that declines to overstate its case. Population-level testing shows no general cerebellar deficit in ordinary migraine, and the authors state the cerebellum is neither a demonstrated attack generator nor a validated treatment target.

Read the review →

Calcified brain lesions left behind by neurocysticercosis have been treated as inert evidence of past infection. This review gathers evidence of intermittent inflammation around them, with swelling and blood-brain barrier leakage, activating the same trigeminovascular pathways that produce migraine.

Read the review →
Blog

CGRP Migraine Injections and Miscarriage Risk: What a New JAMA Neurology Study Found The 7,579-pregnancy cohort written up in full, including what a 42 percent higher adjusted risk does and does not mean.

Read the post →
Blog

Migraine and Glaucoma: What a 3.6 Million-Person Meta-Analysis Found Why the association was strongest in clinic samples and self-reported diagnoses, and what the absolute risk looks like.

Read the post →
Blog

Why I Made Unraveling Migraine Free on Amazon Dave on the reasoning behind giving the book away.

Read the post →
Monday, October 19, 2026

Among 152 people with episodic migraine, cutaneous allodynia was present in 64 percent overall, but almost the entire increase happened at one step: 45 percent in the lowest disability grade against 79 percent in the next one up. Gaps between the higher grades were not significant. One center, one timepoint, one author, described as exploratory.

Read the study →

143 people with migraine and 49 controls had brain blood flow measured. Reduced flow in a hippocampal region among those with depressive symptoms disappeared once the analysis adjusted for sleep quality. Higher flow in a right cerebellar and occipitotemporal region among people with aura did hold, surviving adjustment for sleep, medication overuse and preventives.

Read the study →
Saturday, October 17, 2026

38,472 adults in Pittsburgh. After a subspecialty headache center visit, 12.6 percent ended up in an emergency department, urgent care or hospital within 90 days, against 15.4 percent after general neurology, which is 15 percent lower odds after adjustment. Not randomized, and the two clinics do not see identical patients.

Read the study →

What happens when you stop an anti-CGRP antibody: burden generally climbs back toward baseline within three months, but two or three years of treatment beat stopping at one, and relapse became less likely after the third year. Restarting works about as well as the first course. The authors argue insurer-mandated breaks should be reconsidered.

Read the review →

Nerve blocks in children, 39 studies across three decades from Seattle Children's and CHOP. Consistently described as safe and helpful, with the greater occipital nerve the usual target, but almost all the evidence is observational and nobody does the procedure the same way twice.

Read the review →

Two days after a Milan study found no glymphatic differences in migraine, a review argued the brain's overnight clearance system is the bridge between poor sleep and migraine, proposing four mechanisms including CGRP interfering with meningeal lymphatic drainage. Plausible hypothesis, human evidence not there yet.

Read the review →
Thursday, October 15, 2026

A model trained on MRI scans from healthy people aged 8 to 95 estimated how old a brain looks. Migraine brains came out 3.7 years older than their owners and persistent post-traumatic headache 4.7, against essentially zero for controls. Among people with fresh post-traumatic headache, those whose brains already looked older were the ones still in pain at three and six months. Brain age is a statistical summary of structural differences, not literal aging.

Read the study →

Italy's headache registry, 3,477 patients across 30 centers. Those over 60 had chronic migraine and medication overuse more often and more migraine days, but lower pain intensity and fewer severe attacks. Aura skewed younger. Older patients had been given beta blockers and onabotulinumtoxinA (Botox) more often, while anti-CGRP prescribing did not differ by age.

Read the study →

The entire evidence base for CGRP drugs in under-18s is one randomized trial, of fremanezumab (Ajovy) in 6 to 17 year olds, plus a handful of real-world reports. Eight years after these drugs became standard in adults, the trials that will settle pediatric use are still running.

Read the review →

A Madrid children's hospital reviewed 3,646 emergency visits for headache. Of the 30 admitted children with a primary headache, 63 percent had a head CT and 23 percent an MRI, and not one scan found an acute abnormality or secondary cause. The authors argue for more selective imaging in children who look reassuring on examination.

Read the study →
Wednesday, October 14, 2026

75 people in Japan took lasmiditan (Reyvow) for 180 real attacks. 61 percent had meaningful relief at two hours, but 81 percent reported a side effect, most often drowsiness. People who got drowsy did worse at 24 hours than people who did not. A quarter used it as their only acute treatment anyway.

Read the study →

The glymphatic theory of migraine took a hit. 120 people scanned against 52 controls showed no difference at all in the main measure of perivascular fluid movement, not versus controls, not episodic versus chronic, not during a headache versus free of one. The narrower changes that did appear looked state-dependent rather than fixed.

Read the study →

Amylin, a close relative of CGRP, measured in 121 people with migraine and 63 controls, then again after 24 weeks on erenumab (Aimovig). No difference on any comparison. The authors suggest the signaling that matters happens where a vein in the arm does not sample. There is still no blood test for migraine.

Read the study →

Jes Olesen turned 85 and was interviewed about how the discoveries actually happened: the human provocation model, cortical spreading depression during aura, and the headache classification the field still uses. Sixty years of one method took migraine from unmeasurable to a molecular target with drugs built against it.

Read the interview →
Tuesday, October 13, 2026

JAMA Neurology followed 7,579 pregnancies in people with pre-existing migraine. Anti-CGRP antibody exposure in early pregnancy came with a 42 percent higher risk of miscarriage after adjustment, holding at 33 percent in bias-adjusted analysis, while propranolol (Inderal) showed no increase. CGRP has a role in placental development. Claims data cannot prove cause, but this is a cohort with a comparison group, unlike the manufacturer case series published the day before.

Read the study →

Blood levels of candesartan (Atacand) in 166 people starting it for prevention varied enormously at the same dose, and higher levels meant fewer headache days. Side effects did not track with level. Responders clustered between roughly 63 and 140 nmol per liter, the first published target, which suggests some non-responders never reached a working level.

Read the study →

US military records compared 831,050 service members in high blast overpressure jobs against 2,229,594 who were not. Traumatic brain injury ran 43 percent higher, and migraine diagnoses accumulated faster the longer people stayed in those roles, pointing at repeated subconcussive blast from training rather than combat.

Read the study →

A review of headache in Indigenous communities across four countries, done with Indigenous knowledge keeper guidance. US national data put Indigenous Americans above every other group for prevalence, yet across 45 years the search found 30 publications and not one treatment trial that included Indigenous patients.

Read the review →
Monday, October 12, 2026

1,828 people at a Seoul headache clinic split four ways on what exercise does to their head: 48 percent no connection, 24 percent provoked, 25 percent improved while moving. Chronic migraine carried two and a half times the odds of provocation, and also higher odds of improvement. Blanket advice to exercise more is wrong for a quarter of people.

Read the study →

Eli Lilly pooled 52 clinical trial and 426 postmarketing pregnancies exposed to galcanezumab (Emgality) and found no safety signal. Nearly all exposure was first trimester only and follow-up was missing for many cases, and the company's own conclusion was that no definitive safety statement could be made.

Read the study →

Sensory testing on headache-free days in 65 patients and 51 controls. Migraine ran more sensitive to temperature at both the head and the hand, tension-type headache less so but more pressure-sensitive at the head. Headache frequency made no difference, which argues these are stable traits.

Read the study →
Blog

Opioids for Migraine: What a 12,612-Person International Survey Found Nearly one in four people across six countries were using opioids for migraine, with more disability, worse self-reported thinking problems, and far more emergency visits.

Read the post →
Saturday, October 10, 2026

Eleven women with both migraine and epilepsy stayed on stable seizure medication while starting an anti-CGRP drug. Over a year headache days fell from 18.5 to 5.4 a month and seizure frequency did not rise. The first long-term look at a question people ask constantly, but eleven people with no control group cannot establish safety.

Read the study →

A review of migraine and obesity. Excess weight is linked to more frequent attacks and more disability, with weaker evidence the other way around. The paper argues against preventives that cause weight gain and examines where GLP-1 drugs might fit.

Read the review →

330 adults in Lahore given topiramate (Topamax) or amitriptyline, with topiramate concluded slightly better. Headache days fell from 20.4 a month to about 1.0 in both arms, which is far outside the randomized record for either drug, and allocation was not randomized. Check how the outcome was counted before repeating the number.

Read the study →

This page is for information only and is not medical advice. Talk to your own clinician about your care.

Guided practice

Alternate nostril breathing

A 5-minute guided practice for migraine prevention, from Unraveling Migraine. Captions are built into the video.

  • Prevention, not a rescue. Keep your usual medicine for migraine attacks.
  • Daily practice is what counts. The study behind it used 3 short sessions a day for 3 months.
  • Skip it or stop if your nose is blocked or it starts to feel like a strain.
Read the full guide and the research